NanoKine Option™

Description

Ingredients in NanoKine Option™ are a novel, very potent immune enhancing and modulating, patented 7x homeopathic preparation, with additional patents pending.

This ultra-potent NanoKine Option™ has been diluted, potentized and prepared according to accepted homeopathic practices. One to ten drops per day is taken under the tongue. Each dose contains 333 nanograms of active ingredients, a single drop contains over a trillion molecules (about 1,000,000,000,000,000,000 molecules) but is still less than one-millionth the dose of traditional pharmaceutical drugs.

NanoKine Option™, a small organic molecule with molecular weight of 724, is a chemical combination of the nutrient taurine and a derivative of the amino acid alanine.

Taurine is an important nutrient in the development and support of brain and retinal tissue while alanine is a portion of Vitamin B5.

The molecule in NanoKine™ Option activates, strengthens and modulates, or adjusts, the patients immune defense system to combat a number of specific immune related ailments, (e.g. fatigue, allergies, colds and flu).

Initial use of ingredients in NanoKine Option™ produced allergy reduction and simultaneously reduced fatigue, even in patients with chronic fatigue (CFS), and potentially fatal Hepatitis-C (HCV). HCV viral count was also reduced. There are an estimated 4 million people in the U.S. with HCV, which currently has no non-toxic or reproducibly effective therapy.

NanoKine Option™ has shown a significant response rate in clinical trials for the reduction of symptoms in chronic fatigue and fibromyalgia: an average rate of 80% after 4 weeks of use and 90% after 8 weeks. Ingredients in NanoKine Option™ Eliminated cancer cells in several animal studies:

- 80% survival, for mice injected with myeloma cancer cells; all untreated mice died.
- 70% survival, for mice injected with melanoma cancer cells; all untreated mice died.
- Ongoing survival - 2 dogs with terminal cancer (fibrosarcoma, T-cell lymphoma).

The dog with fibrosarcoma was given 6 months to live (9/02). As of 4/02, the dog is alive, 13 months beyond original prognosis. The dog with T-cell lymphoma is reported to have greater quality of life, better than expected liver enzymes and less than expected progression of disease.

Following is a summary of research conducted on the mechanism of action, effectiveness and safety in animal studies and effectiveness and safety in human trials:

In extensive cell research it was determined that ingredients in NanoKine Option™ modulate the immune system in a manner conducive to fighting disease. It was deduced that the in-vivo mechanism of action of NanoKine Option™ might be through T-cell activation leading to increased cytokine production. It was found in vitro that:

1. Ingredients in NanoKine Option™ activates T-cells, increasing intracellular calcium, CD 69 expression and Peripheral Mononuclear cells in culture.

2. Ingredients in NanoKine Option™ stimulates tumor necrosis factor (TNF-alpha) and interferon gamma.

3. Ingredients in NanoKine Option™ mediated presence of surface TNF-alpha killed HL60 tumor cells.

Note: The information provided herein should not be used for diagnosis or treatment of any medical condition. A licensed physician should be consulted for diagnosis and treatment of any and all medical conditions.